评述："PSCA CAR 工程化 Vδ1 γδ T 细胞用于胰腺癌免疫治疗的疗效与安全性比较"

Commentary on "Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer".

快速制备的 CD276 CAR-T 细胞在胰腺癌中展现增强的持久性和疗效

Rapidly-manufactured CD276 CAR-T cells exhibit enhanced persistence and efficacy in pancreatic cancer.

在本研究中，我们证明 CD276 CAR-T 在体外和体内均对胰腺癌细胞表现出强大的活性。

CAR-T 细胞治疗胰腺癌的进展、挑战与创新策略

Advances, challenges, and innovative strategies of CAR-T cell therapy in pancreatic cancer.

CAR-NK 细胞联合 CAR-巨噬细胞治疗胰腺癌的协同抗肿瘤活性

Synergistic antitumor activity of CAR-NK cells combined with CAR-macrophages for pancreatic cancer treatment.

基于纳米抗体的 CAR-M 与 CAR-NK 联合疗法重编程 TME，并在巨噬细胞与 NK 细胞之间建立起由 CXCL9 驱动的前馈环路，从而产生协同的固有免疫激活和强效的肿瘤控制。

携带靶向 Trop2 全人源 scFv 的 CAR-T 细胞可用于治疗胰腺癌

CAR T cells equipped with a fully human scFv targeting Trop2 can be used to treat pancreatic cancer.

这些结果表明，装备了全人源抗 Trop2 scFv 的 Trop2 靶向 CAR-T 细胞可能成为胰腺癌的潜在治疗策略，并可能有助于临床评估。

CAR-T 疗法革新胰腺癌治疗

Revolutionizing pancreatic cancer treatment with CAR-T therapy.

胰腺癌细胞免疫治疗的下一波浪潮

The next wave of cellular immunotherapies in pancreatic cancer.

多组学驱动的精准策略克服胃肠道恶性肿瘤中 CAR-T 治疗的局限性

Multi-Omics-Enabled Precision Strategies for Overcoming CAR-T Therapy Limitations in Gastrointestinal Malignancies.

CAR-T 疗法在实体瘤中的应用：当前机遇与挑战

Application of CAR-T therapy in solid tumors: current opportunities and challenges.

用 CD44 靶向配体对 NK 细胞进行表面工程以增强癌症免疫治疗

Surface Engineering of Natural Killer Cells with CD44-targeting Ligands for Augmented Cancer Immunotherapy.